We retrospectively analyzed the patients who received azacitidine in our center in the course of treatment of their post-transplant relapse. We identified 31 patients. Relapse occurred at a median ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, and safety of azacitidine are reviewed. Summary: Azacitidine is the first drug in a new class of ...

If you are worried about using this medicine, speak to your doctor or pharmacist. Azacitidine-Teva contains the active ingredient azacitidine. Azacitidine-Teva is used to treat myelodysplastic ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with ...

Azacitidine is an antineoplastic agent, prescribed for blood cancer. The risk or severity of adverse effects can be increased when Azacitidine is combined with Bacillus calmette-guerin substrain ...

Under the direction of Dr. Guru Subramanian Guru Murthy at the Medical College of Wisconsin Cancer Center, the trial ( NCT06502145) will evaluate the safety, tolerability, and recommended Phase II ...

The phase III SELECT-MDS-1 study evaluated tamibarotene in combination with azacitidine, a chemotherapy, in newly diagnosed HR-MDS patients with RARα gene overexpression. Per the data readout ...

Citing Phase 1 data the company announced, Citi analyst Yigal Nochomovitz noted that SL-172154 with chemotherapy azacitidine ...